A 2026 scientific review explored the relationship between the endocannabinoid system, cannabinoids, the gut and skin microbiome, and melanoma. Researchers noted that although targeted therapies and immunotherapies have improved melanoma treatment, treatment resistance and adverse effects remain significant challenges. Preclinical research suggests that cannabinoids may influence cancer cells and immune activity, prompting interest in compounds […]
Category: CBG
Cannabinoid-Based Neuroimmune Treatment and Survival in Advanced Cancer (pub. Aug 2026)
Researchers evaluated a neuroimmune treatment combining angiotensin 1-7 (Ang 1-7), melatonin, 5-methoxytryptamine, and cannabinoids in 100 patients with advanced solid tumors who had exhausted standard treatment options. Compared with a historical group that received pineal indoles and cannabinoids without Ang 1-7, patients receiving the full regimen had higher rates of disease control and tumor regression. […]
Major Cannabinoids Influence Different Genetic Pathways Linked to Inflammation, Cell Stress, and Neurological Function (pub. May 2026)
A 2025 study compared the effects of four major cannabinoids found in hemp extract—CBD (cannabidiol), CBG (cannabigerol), CBC (cannabichromene), and THC (tetrahydrocannabinol)—to better understand how each compound affects gene activity within cells. Using transcriptomic analysis, researchers examined changes in gene expression after cannabinoid exposure and found that each cannabinoid produced distinct biological responses. The findings […]